Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Cost-Containment Mechanisms for Essential Medicines, Including Antiretrovirals, in China - Health Economics and Drugs Series No. 013
(2003; 30 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentTerms of reference
Open this folder and view contentsIntroduction
View the documentBackground and experiences with voluntary agreements
View the documentCountry rights to be protected in voluntary agreements for reduction of prices of medicines
Open this folder and view contentsCompulsory licensing - practical aspects and procedures
View the documentConcluding comments
View the documentList of persons contacted
View the documentFurther reading
 

Terms of reference

Following meetings between the Chinese Ministry of Health (MOH) and the World Health Organization Representative in China, the MOH requested WHO to provide technical assistance on cost-containment mechanisms for antiretrovirals (ARVs) and other essential medicines in China.

The MOH requested information in the following areas:

1. The range of cost-containment options for ARVs and other essential medicines that China might consider.

2. Lessons from other countries' experience in negotiating price discounts and voluntary licensing arrangements for ARVs and other essential medicines.

3. China's World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Agreement (TRIPS) compatible options to undertake compulsory licensing; and the modalities of how a compulsory licence might be issued in China.


Germán Velásquez, Coordinator of the Drug Action Programme within WHO’s Department of Essential Drugs & Medicines Policy, headed a three-person delegation that went to China, from 11 to 13 December 2002, for meetings with the MOH and other Chinese agencies. He was accompanied by Professor Carlos Correa of the University of Buenos Aires and Robert Weissman, an attorney practicing in Washington, D.C., who served as expert consultants on licensing and intellectual property issues.

This report contains a short summary of issues discussed during the mission in the area of cost-containment mechanisms and policies for access to essential medicines.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014